Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Bond Index Fund ETF vs CVS Health Corp — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.93, while CVS Health Corp trades at $93.67 (market cap $122.36B). The key difference: CVS Health Corp pays a 2.78% dividend while Vanguard Total International Bond Index Fund ETF pays none, and CVS Health Corp is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | CVS | |
|---|---|---|
52-Week High | $49.91 | $110.60 |
52-Week Low | $47.57 | $64.88 |
Market Cap | — | $122.36B |
Sector | — | Health |
Enterprise Value | — | $184.71B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNDX, the Vanguard Total International Bond ETF, trades at $47.95, up 0.13% on the day. The technical outlook is neutral overall, with bearish moving averages and neutral oscillators. Recent corporate actions include scheduled dividend payments in 2026. Market sentiment is influenced by global bond yield fluctuations and institutional trading activity, as seen with Apella Capital reducing its stake and Archer Investment Management increasing its holdings.
The outlook for BNDX is tied to international bond market dynamics, with opportunities from investor demand for yield but risks from inflation data and geopolitical tensions affecting Treasury yields. Key risks include interest rate uncertainty and oil price volatility, which could pressure bond performance. Institutional interest remains mixed, reflecting cautious optimism amid macroeconomic headwinds.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
